Enzalutamide,
does it really help with Prolong overall survival in men with metastatic castration-resistant prostate cancer after docetaxel?
research showsEnzalutamide is rated A with 92 points because it prolongs overall survival in men with metastatic castration-resistant prostate cancer that progressed after docetaxel. In the 1,199-participant phase 3 randomized double-blind placebo-controlled AFFIRM trial, median overall survival was 18.4 versus 13.6 months and the hazard ratio for death was 0.63 (95% CI 0.53 to 0.75); the trial was stopped for efficacy at the planned interim analysis. Radiographic progression-free survival, prostate-specific antigen response, pain, quality of life, and skeletal events moved in the same direction. A single pivotal manufacturer-funded trial is a limitation, but this is a large prescription oncology trial with a hard survival endpoint, so the manufacturer or branded-ingredient ceiling does not apply. Fatigue, hypertension, falls, fractures, cognitive effects, and uncommon seizures remain separate from survival efficacy under safety.
ads claimProlonged survival does not mean that every patient lives exactly 4.8 additional months or that the cancer disappears. The median difference is a group comparison, and subsequent therapies, performance status, metastatic sites, earlier androgen-receptor-targeted treatment, and resistance alter individual outcomes.
Useful facts when choosing a product
- Enzalutamide is an oral prescription anticancer medicine with a representative recommended dose of 160 mg once daily with or without food. Capsules or tablets should be swallowed whole as directed, and the oncology or urology prescription takes priority.
- Patients who have not undergone bilateral orchiectomy generally continue a gonadotropin-releasing hormone analog to maintain castration. Unsupervised stopping or dose reduction can complicate assessment of disease progression and toxicity.
- Fatigue, hypertension, hot flushes, diarrhea, decreased appetite, falls, and fractures can occur, while seizures and posterior reversible encephalopathy syndrome are uncommon. Driving risk, falls, bone health, and neurologic symptoms require monitoring.
- Enzalutamide strongly induces several cytochrome P450 enzymes and can lower exposure to warfarin and many other medicines, while strong CYP2C8 inhibitors and enzyme inducers can alter enzalutamide exposure. The cancer team should review every medicine and supplement.
What the research actually shows
Scher and colleagues in 2012 randomized 1,199 men with metastatic castration-resistant prostate cancer progressing after chemotherapy to enzalutamide 160 mg daily in 800 participants or placebo in 399. At the planned interim analysis after 520 deaths, median overall survival was 18.4 versus 13.6 months and the hazard ratio for death was 0.63, leading to trial termination for benefit. Radiographic progression-free survival was 8.3 versus 2.9 months with a hazard ratio of 0.40, and a prostate-specific antigen decline of at least 50% occurred in 54% versus 2%. The prespecified Fizazi secondary analysis reported time to first skeletal event of 16.7 versus 13.3 months, time to quality-of-life deterioration of 9.0 versus 3.7 months, and improved pain measures. An independent 2022 network meta-analysis of five trials and 3,862 participants after docetaxel failure estimated an overall-survival hazard ratio of 0.58 for enzalutamide versus supportive care, although indirect comparison does not replace the direct AFFIRM result.
Why this is classified as A (92)
The 1,199-participant double-blind placebo-controlled phase 3 AFFIRM trial used overall survival as its primary endpoint and showed 18.4 versus 13.6 months with a death hazard ratio of 0.63, a clear direct hard-outcome benefit. Radiographic progression-free survival, prostate-specific antigen response, pain, quality of life, and skeletal events were consistent, and a post-docetaxel network synthesis reinforced survival direction. Manufacturer funding does not trigger the branded-evidence ceiling for a large prescription-drug hard-outcome trial, supporting A with 92 points. Fatigue, hypertension, falls, fractures, seizures, and interactions are separate safety issues.
Counterpoint. AFFIRM applies to the specific postchemotherapy metastatic castration-resistant setting. Treatment sequence should be individualized for earlier abiraterone or androgen-receptor inhibitor exposure, other available survival-prolonging therapies, symptoms, genomics, and patient preferences.
Rejudgment record. Cross-verification incorporated — Applied A because the 1,199-participant double-blind placebo-controlled phase 3 AFFIRM trial significantly prolonged the hard endpoint of overall survival from 13.6 to 18.4 months with a death hazard ratio of 0.63 and showed consistent radiographic progression, pain, quality-of-life, and skeletal outcomes, using the exception that does not impose a manufacturer ceiling on a large prescription-drug hard-outcome randomized trial
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prolonged overall survival after docetaxel in metastatic castration-resistant prostate cancer | A | AFFIRM directly demonstrated a hard survival benefit in 1,199 participants: 18.4 versus 13.6 months and a death hazard ratio of 0.63. |
| Prolonged radiographic progression-free survival after docetaxel in metastatic castration-resistant prostate cancer | B | The AFFIRM secondary endpoint was 8.3 versus 2.9 months with a hazard ratio of 0.40, but it is more surrogate than overall survival. |
| Increased prostate-specific antigen response of at least 50% after docetaxel in metastatic castration-resistant prostate cancer | B | A prostate-specific antigen decline of at least 50% occurred in 54% versus 2%, but this biomarker response was kept distinct from survival evidence. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Scher HI et al. 2012 AFFIRM | Phase 3 multinational randomized double-blind placebo-controlled trial | 399 | Medivation and Astellas Pharma Global Development | Primary overall survival with secondary radiographic progression-free survival, prostate-specific antigen response, and quality-of-life outcomes | Median overall survival was 18.4 versus 13.6 months with a death hazard ratio of 0.63; radiographic progression-free survival was 8.3 versus 2.9 months. | Core large randomized direct survival evidence |
| Fizazi K et al. 2014 AFFIRM secondary analysis | Prespecified analysis of patient-centered secondary endpoints | 1,199 | Medivation and Astellas | Skeletal-related events, pain, and health-related quality of life | Time to first skeletal event was 16.7 versus 13.3 months and time to quality-of-life deterioration was 9.0 versus 3.7 months, reinforcing patient-centered benefit. | Patient-centered reinforcement consistent with the survival effect |
| Chen J et al. 2022 network meta-analysis | Systematic review and Bayesian network meta-analysis of randomized systemic-therapy trials after docetaxel failure | 3,862 | Public and academic support including the National Natural Science Foundation of China | Overall survival, biochemical progression-free survival, and serious adverse events | The estimated overall-survival hazard ratio for enzalutamide versus supportive care was 0.58 with a 95% credible interval of 0.49 to 0.69. | Independent synthesis with indirect-comparison limitations |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-21).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-21 · Corrections: none
Cite this verdict
[Chamgap] Enzalutamide x prolonged overall survival after docetaxel in metastatic castration-resistant prostate cancer — Evidence Grade A·92. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/enzalutamide-post-docetaxel-metastatic-castration-resistant-prostate-cancer-survival/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.